Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-11-30
2009-02-17
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07491702
ABSTRACT:
The invention provides compounds having formulae comprisingin-line-formulae description="In-line Formulae" end="lead"?X1-Ser-Met-Arg-Glu-Arg-X2in-line-formulae description="In-line Formulae" end="tail"?in which X1and X2are up to 30 amino acid residues and the formula represents a reverse-order sequence corresponding to amino acid residues 332 to 328 of human APP and from zero to 30 successive amino acid residues of human APP extending in each direction therefrom, The invention also provides the pentapeptide Ser-Met-Arg-Glu-Arg, corresponding to residues 332 to 328 of human amyloid precursor protein in reverse order, and the tripeptide Arg-Glu-Arg which corresponds residues 328 to 330 of human amyloid precursor protein, the tripeptide and pentapeptide being provided as pharmaceutical compositions. The invention further provides conjugates of the foregoing compounds which can cross the blood-brain barrier and pharmaceutical compositions containing such conjugates. The compounds and compositions of the invention are believed to be useful in the treatment of Alzheimer's disease and as cognitive enhancers and appropriate methods of medical treatment are disclosed.
REFERENCES:
patent: 660843 (1900-10-01), Feige et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4565804 (1986-01-01), Rivier et al.
patent: 4707468 (1987-11-01), Yoshino et al.
patent: 4810636 (1989-03-01), Corey
patent: 5028592 (1991-07-01), Lipton
patent: 5493008 (1996-02-01), Fox et al.
patent: 5639726 (1997-06-01), Lawrence et al.
patent: 5777083 (1998-07-01), Burnie et al.
patent: 5958883 (1999-09-01), Snow
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6214797 (2001-04-01), Vale, Jr. et al.
patent: 2003/0032593 (2003-02-01), Wender et al.
patent: 58-183656 (1983-10-01), None
patent: WO 94/09808 (1994-05-01), None
patent: WO 97/00063 (1997-01-01), None
patent: WO 97/04748 (1997-02-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/21327 (1998-05-01), None
patent: WO 99/57305 (1999-11-01), None
patent: WO 99/58564 (1999-11-01), None
patent: WO 99/67284 (1999-12-01), None
patent: WO 00/69900 (2000-11-01), None
Curtain, et al.: “Fusogenic activity of amino-terminal region of HIV type 1 Nef protein”Aids Research And Human Retroviruses10(10): 1231-40 (Oct. 1994).
James, et al.: “Basic amino acids predominate in the sequential autoantigenic determinant of the small nuclear 70K ribonucleoprotein”,Scandinavian Journal Of Immunology39(6):557-66 (1994).
Koo, et al., “Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth”,Proc. Natl. Acad. Sci. USA90:4748-4752 (May 1993).
Merrifield, B: “Solid Phase Synthesis”Science, 232(18)341-347 (Apr. 18, 1986).
Rist, et al: “The bioactive conformation of neuropeptide Y analogues at the human Y-2-receptor”,European Journal Of Biochemistry247(3)1019-1028 (1997).
Multhaup, et. al.; “Characterization of the High Affinity Heparin Binding Site of the Alzheimer's Disease βA4 Amyloid Precursor Protein (APP) and its Enhancement by Zinc(II)”;Journal of Molecular Recognition, vol. 8. 247-257 (1995).
Kang, et al.; “The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor”;Nature, vol. 325 Feb. 19, 1987.
Mileusnic, et al.; “APP is required during an early phase of memory formation”,European Journal of Neuroscience, vol. 12, pp. 4487-4495, 2000.
Abe, et al.; “Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo”;Brain Research636 (1994) 162-164.
Barnes, et al.; “Increased Production of Amyloid Precursor Protein Provides a Substrate for Caspase-3 in Dying Motoneurons”;The Journal of Neuroscience, Aug. 1, 1998, 18(15):5869-5880.
Cleary, et al.; “Beta-amyloid (1-40) effects on behavior and memory”;Brain Research 682(1995) 69-74.
Davis, et al.; “Autoradiographic Distribution of L-Proline in Chicks After Intracerebral Injection”;Physiology&Behavior, vol. 22, pp. 693-695.Pergamon Press and Brain Research Publ., 1979.
Doyle, et al.; “Intraventricular infusions of antibodies to amyloid-β-protein precursor impair the acquisition of a passive avoidance response in the rat”;Neuroscience Letters, 115 (1990) 97-102Elsevier Scientific Publishers Ireland Ltd.
Flood, et al.; “Amnestic effects in mice of four synthtic peptides homologous to amyloid β protein from patients with Alzheimer disease”;Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3363-3366, Apr. 1991Neurobiology.
Goodman, et al.; “Secreted Forms of β-Amyloid Precursor Protein Protect Hippocampal Neurons against Amyloid β-Peptide-Induced Oxidative Injury”;Experimental Neurology 128, 1-12 (1994).
Goodman, et al.; “K+ channel openers protect hippocampal neurons against oxidative injury and amyloid β-peptide toxicity”;Brain Research 706(1996) 328-332.
Huber, et al.; “Synaptic β-Amyloid Precursor Proteins Increase with Learning Capacity in Rats”;Neuroscience, vol. 80, No. 2, pp. 313-320, 1997.
Huber et al.; “Involvement of amyloid precursor protein in memory formation in the rat: an indirect antibody approach”;Brain Research, 603 (1993) 348-352.
Ishida, et al.; “Secreted form of β-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices”;Neuro Report 8. 2133-2137 (1997).
Jinn, et al.; “Peptides Containing the RERMS Sequence of Amyloid β/A4 Protein Precursor Bind Cell Surface and Promote Neurite Extension”;The Journal of Neuroscience, Sep. 1994, 14(9): 5461-5470.
LeBlanc, et al.; “Role of Amyloid Precursor Protein (APP): Study with Antisense Transfection of Human Neuroblastoma Cells”;Journal of Neuroscience Research 31:635-645 (1992).
Li, et al.; “Defective Neurite Extension Is Caused by a Mutation in Amyloid β/A4 (Aβ) Protein Precursor Found in Familial Alzheimer's Disease”;J. Neurobiol., 32, 469-480 (1997).
Lossner, et al.; “Passive Avoidance Training Increases Fucokinase Activity in Right Forebrain Base of Day-Old Chicks”;Journal of Neurochemistry, 41 1357-1363 (1983).
Mattson, et al.; “β-Amyloid precursor protein metabolites and loss of neuronal Ca2+homeostasis in Alzheimer's disease”;TINS, vol. 16, No. 10, 1993.
Mattson, et al.; “Evidence for Excitoprotective and Intraneuronal Calcium-Regulating Roles for Secreted Forms of the β-Amyloid Precursor Protein”;Neuron, vol. 10, 243-254, Feb. 1993.
Mark P. Mattson; “Secreted Forms of β-Amyloid Precursor Protein Modulate Dendrite Outgrowth and Calcium Responses to Glutamate in Cultured Embryonic Hippocampal Neurons”;J. Neurobiol., 25, 439-450 (1994).
Maurice, et al.; “Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction”;Brain Research 706(1996) 181-193.
Meziane, et al.; “Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice”;Proc. Natl. Acad. Sci. USA, vol. 95, pp. 12683-12688, Oct. 1998.
Mucke, et al.; “Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice”;Brain Research 666(1994) 151-167.
Muller, et al.; “Behavioral and Anatomical Deficits in Mice Homozygous for a Modified β-Amyloid Precursor Protein Gene”;Cell, vol. 79, 755-765, Dec. 2, 1994.
Ninomiya, et al.; “Amino Acid Sequence RERMS Represents the Active Domain of Amyloid β/A4 Protein Precursor that Promotes Fibroblast Growth”;The Journal of Cell Biology, vol. 121, No. 4, May 1993 879-886.
Roch, et al.; “Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid &#x
Mileusnic Radmila
Rose Steven Peter Russell
Drinker Biddle & Reath LLP
Saoud Christine J
Seharaseyon Jegatheesan
The Open University
LandOfFree
Polypeptides related to amyloid precursor protein,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides related to amyloid precursor protein,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides related to amyloid precursor protein,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081233